Feed XCUR
XC

Exicure, Inc.

XCUR · NASDAQ

$1.25 +0.56% (+$0.01)
1M +6.96%
Market Cap $8.60M
P/E Ratio -
Div. Yield -
ROE 237.91%
Piotroski F-Score Weak
1/9
Valuation
0 /100
Expensive
P/B 8.81x
P/E N/A
EV/EBITDA N/A
Growth
0 /100
Declining
Book val. growth 35.92%
EPS growth N/A
Rev. growth N/A
Profitability
-
N/A
Gross margin N/A
Net margin N/A
Op. margin N/A
Quality
0 /100
Poor
ROIC 93.88%
ROE 237.91%
ROA 72.69%
Debt
48 /100
Moderate
Debt/Equity 0.00x
Current ratio 0.56x
Int. coverage -8,917.00x
Stability
1 /100
Unstable
Beta 3.62x
EPS volatility 181.89%
Profitable years 0

Bulios Scoring opisuje kakovost in preteklost podjetja, ne prihodnjega donosa. Visok rezultat ni nakupni signal. Izvedite več

Vprašajte StockBota o XCUR
Online

O podjetju

Exicure, Inc. is a biopharmaceutical company focused on developing novel therapeutics based on the technology of therapeutic coding. Its main product platform is based on a technology called Spherical Nucleic Acid (SNA™), which enables the creation of three-dimensional structures of nucleic acids that have the potential to modulate gene expression. Exicure aims to utilize this technology to develop therapeutics for various indications, including oncological diseases, dermatological conditions, and neurological disorders. The company also engages in research and development of therapeutic vaccines based on SNA™ technology. Exicure collaborates with pharmaceutical companies and academic institutions on the development and commercialization of its products. Shares of Exicure, Inc. may be an interesting investment opportunity for investors following the pharmaceutical industry and biopharmaceutical research.

V vašem jeziku še ni na voljo, zato je besedilo v angleščini.

Sector

Healthcare

Industry

Biotechnology

CEO

Jungsoo Kim

Employees

1

Headquarters

Redwood City

Prihajajoči dogodki

12 NOV.

Earnings

Upcoming earnings report

52d

Uporabljamo nujne piškotke za delovanje spletnega mesta in izbirne analitične piškotke za merjenje uporabe. Preberite naš Pravilnik o zasebnosti.